Plasma Renin Activity Predicts the Improvement in Resistant Hypertension after Percutaneous Transluminal Renal Artery Angioplasty

Objective Percutaneous transluminal renal artery angioplasty (PTRA) has been recommended for the treatment of renovascular resistant hypertension. However, large randomized trials have reported that PTRA did not improve the outcomes compared with optimal medical therapy in patients with renal artery...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2016/12/01, Vol.55(23), pp.3421-3426
Main Authors: Daidoji, Hyuma, Tamada, Yoshiaki, Suzuki, Saya, Watanabe, Ken, Shikama, Taku, Kikuchi, Yoku, Kato, Shigehiko, Takahashi, Katsuaki, Fukui, Akio, Matsui, Motoyuki, Yahagi, Tomoyasu, Goto, Toshikazu
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Angioplasty - methods
Antihypertensive Agents - therapeutic use
Blood Pressure
Female
Humans
Hypertension, Renovascular - surgery
Kidney - physiopathology
Male
Middle Aged
Original
percutaneous renal artery angioplasty
plasma renin activity
Renal Artery
Renal Artery Obstruction - surgery
renal artery stenosis
Renin - blood
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective Percutaneous transluminal renal artery angioplasty (PTRA) has been recommended for the treatment of renovascular resistant hypertension. However, large randomized trials have reported that PTRA did not improve the outcomes compared with optimal medical therapy in patients with renal artery stenosis (RAS). It is important to identify patients with renovascular hypertension who are likely to respond to PTRA. We herein examined whether or not the plasma renin activity (PRA) could predict the improvement in resistant hypertension after PTRA for RAS. Methods and Results A total of 40 patients (mean age: 63±15 years) with unilateral RAS who received PTRA for resistant hypertension were enrolled in this study. Twenty-two (55%) patients experienced a significant reduction in their blood pressure while using few antihypertensive agents at the 3-month follow up. The median PRA was significantly higher in patients using few antihypertensive agents than in those using more [4.2 ng/mL/hr, interquartile range (IQR) 2.6-8.0 vs. 0.8 ng/mL/hr, IQR 0.4-1.7, p2.4 ng/mL/hr) was an independent predictor of the improvement in hypertension after PTRA (odds ratio: 22.3, 95% confidence interval: 2.17 to 65.6, p
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.55.7312